The role of cholesterol metabolism in tumor therapy, from bench to bed.
cholesterol
cholesterol metabolism
clinical trial
pharmacological targets
tumor therapy
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
04
2022
accepted:
28
03
2023
medline:
24
4
2023
pubmed:
24
4
2023
entrez:
24
04
2023
Statut:
epublish
Résumé
Cholesterol and its metabolites have important biological functions. Cholesterol is able to maintain the physical properties of cell membrane, play an important role in cellular signaling, and cellular cholesterol levels reflect the dynamic balance between biosynthesis, uptake, efflux and esterification. Cholesterol metabolism participates in bile acid production and steroid hormone biosynthesis. Increasing evidence suggests a strict link between cholesterol homeostasis and tumors. Cholesterol metabolism in tumor cells is reprogrammed to differ significantly from normal cells, and disturbances of cholesterol balance also induce tumorigenesis and progression. Preclinical and clinical studies have shown that controlling cholesterol metabolism suppresses tumor growth, suggesting that targeting cholesterol metabolism may provide new possibilities for tumor therapy. In this review, we summarized the metabolic pathways of cholesterol in normal and tumor cells and reviewed the pre-clinical and clinical progression of novel tumor therapeutic strategy with the drugs targeting different stages of cholesterol metabolism from bench to bedside.
Identifiants
pubmed: 37089950
doi: 10.3389/fphar.2023.928821
pii: 928821
pmc: PMC10117684
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
928821Informations de copyright
Copyright © 2023 Xia, Wang, Zhou, Wang, Xue, Cao and Song.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Rev Mol Cell Biol. 2020 Apr;21(4):225-245
pubmed: 31848472
J Exp Clin Cancer Res. 2010 Sep 16;29:127
pubmed: 20843370
Front Oncol. 2021 May 24;11:682911
pubmed: 34109128
Breast Cancer Res Treat. 2012 Jan;131(2):709-11
pubmed: 22089963
Circulation. 2019 Jun 18;139(25):e1082-e1143
pubmed: 30586774
J Mol Cell Cardiol. 2022 Feb;163:1-8
pubmed: 34582824
Indian J Med Res. 2019 Dec;150(6):630-634
pubmed: 32048627
Nature. 2019 Mar;567(7746):118-122
pubmed: 30760928
Front Oncol. 2020 Jul 30;10:882
pubmed: 32850302
Mol Cancer Ther. 2014 Jul;13(7):1690-703
pubmed: 24688051
Mol Oncol. 2018 Oct;12(10):1735-1752
pubmed: 30098223
Nat Commun. 2017 Oct 11;8(1):864
pubmed: 29021522
Mol Pharm. 2020 Jun 1;17(6):1835-1847
pubmed: 32315193
Cell Metab. 2021 Jan 5;33(1):199-210.e8
pubmed: 33152323
Mol Cancer Ther. 2014 Apr;13(4):855-66
pubmed: 24493696
Breast Cancer Res Treat. 2010 Aug;122(3):661-70
pubmed: 19851860
Annu Rev Cell Dev Biol. 2009;25:539-66
pubmed: 19575637
Redox Rep. 2006;11(6):255-62
pubmed: 17207307
PLoS One. 2013 Jun 13;8(6):e65734
pubmed: 23785446
FEBS J. 2019 Nov;286(21):4192-4208
pubmed: 31350867
Ann Oncol. 2012 Oct;23 Suppl 7:vii155-66
pubmed: 22997448
Cancer Cell. 2015 Jul 13;28(1):42-56
pubmed: 26120082
Clin Cancer Res. 2011 Mar 15;17(6):1553-60
pubmed: 21411446
Clin Cancer Res. 2021 Sep 15;27(18):5004-5011
pubmed: 34011557
Pediatr Blood Cancer. 2014 Apr;61(4):636-42
pubmed: 24123865
Cell Metab. 2005 Feb;1(2):121-31
pubmed: 16054053
Cell Metab. 2014 Mar 4;19(3):393-406
pubmed: 24606897
Oncol Rep. 2018 Apr;39(4):1919-1929
pubmed: 29436682
Physiol Rev. 2001 Jan;81(1):153-208
pubmed: 11152757
Sci Rep. 2019 Mar 1;9(1):3306
pubmed: 30824767
Cell. 2012 Jan 20;148(1-2):244-58
pubmed: 22265415
Front Pharmacol. 2013 Sep 25;4:119
pubmed: 24093019
Am J Respir Crit Care Med. 2014 Sep 15;190(6):675-87
pubmed: 25152164
Drug Des Devel Ther. 2020 Aug 26;14:3535-3545
pubmed: 32921987
Cancer Res. 2016 Apr 15;76(8):2063-70
pubmed: 27197250
J Exp Clin Cancer Res. 2020 Jan 30;39(1):24
pubmed: 32000827
J Intern Med. 2019 Apr;285(4):367-380
pubmed: 30478861
BMC Cancer. 2015 Jun 09;15:460
pubmed: 26055977
Cancer Prev Res (Phila). 2014 May;7(5):496-504
pubmed: 24614012
Sci Rep. 2015 Mar 12;5:9054
pubmed: 25761781
J Clin Oncol. 2017 May 10;35(14):1506-1514
pubmed: 28240967
Oncogene. 2010 May 6;29(18):2712-23
pubmed: 20190811
Cancers (Basel). 2020 Jul 14;12(7):
pubmed: 32674461
Nat Metab. 2020 Feb;2(2):132-141
pubmed: 32694690
Biochim Biophys Acta Rev Cancer. 2020 Aug;1874(1):188394
pubmed: 32698040
Oncotarget. 2015 Dec 1;6(38):41018-32
pubmed: 26512780
Prostate Cancer Prostatic Dis. 2020 Dec;23(4):630-637
pubmed: 32203069
Cell Rep. 2012 Sep 27;2(3):580-90
pubmed: 22981231
Nat Commun. 2018 Oct 26;9(1):4490
pubmed: 30367044
Nat Rev Cardiol. 2022 Jun;19(6):414-425
pubmed: 35440740
Cell. 2018 Feb 8;172(4):825-840.e18
pubmed: 29336888
Nat Commun. 2019 Oct 11;10(1):4621
pubmed: 31604910
ACS Nano. 2015 Mar 24;9(3):2420-32
pubmed: 25662106
Molecules. 2018 Aug 03;23(8):
pubmed: 30081476
Cancer. 2011 May 15;117(10):2178-85
pubmed: 21523731
Invest New Drugs. 2021 Feb;39(1):226-231
pubmed: 32851510
Leuk Lymphoma. 2013 Nov;54(11):2534-6
pubmed: 23432687
Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12027-32
pubmed: 14512514
Cancer Res. 2014 Sep 1;74(17):4772-82
pubmed: 24994712
Am J Hematol. 2015 Jun;90(6):483-6
pubmed: 25689471
Cancer Res. 2014 Sep 15;74(18):4976-82
pubmed: 25060521
Oncogene. 2015 Oct 1;34(40):5128-40
pubmed: 25619842
Oncogene. 2017 Nov 16;36(46):6462-6471
pubmed: 28759039
J Hepatol. 2019 Sep;71(3):516-522
pubmed: 31125576
Am J Pathol. 2014 Jul;184(7):2099-110
pubmed: 24952430
Mol Cell Endocrinol. 2018 May 5;466:73-80
pubmed: 28919300
Circulation. 2012 Apr 17;125(15):1905-19
pubmed: 22508840
Clin Cancer Res. 2016 Nov 1;22(21):5337-5348
pubmed: 27281560
Transl Lung Cancer Res. 2019 Oct;8(5):692-699
pubmed: 31737505
Cell Rep. 2016 Apr 12;15(2):336-48
pubmed: 27050512
Anticancer Drugs. 2019 Jun;30(5):495-500
pubmed: 30724772
Annu Rev Pharmacol Toxicol. 2016;56:447-67
pubmed: 26738477
Int J Cancer. 2003 Aug 10;106(1):125-37
pubmed: 12794767
Br J Haematol. 2014 Oct;167(2):233-7
pubmed: 25039477
Science. 2004 Feb 20;303(5661):1201-4
pubmed: 14976318
N Engl J Med. 2012 Nov 8;367(19):1792-802
pubmed: 23134381
Mol Cancer Res. 2018 Jun;16(6):974-985
pubmed: 29545473
Arch Biochem Biophys. 2020 May 15;684:108327
pubmed: 32142890
Onco Targets Ther. 2019 Jan 23;12:773-783
pubmed: 30774365
Nat Commun. 2021 Aug 24;12(1):5103
pubmed: 34429409
Breast Cancer Res Treat. 2010 Jan;119(1):137-44
pubmed: 19728082
Mol Carcinog. 2012 May;51(5):389-99
pubmed: 21563217
Mini Rev Med Chem. 2013 Jun 1;13(8):1195-219
pubmed: 23198718
Arch Pharm Res. 2019 Jan;42(1):25-39
pubmed: 30536027
Am J Transl Res. 2020 Feb 15;12(2):428-446
pubmed: 32194894
J Biol Chem. 2007 Jun 29;282(26):18777-85
pubmed: 17483544
Pharm Res. 2008 May;25(5):1134-41
pubmed: 18080173
Nat Cell Biol. 2014 Apr;16(4):357-66
pubmed: 24658687
Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11140-5
pubmed: 18682566
Cancer Manag Res. 2020 Jun 17;12:4645-4665
pubmed: 32606957
Biochemistry. 2016 Oct 4;55(39):5483-5506
pubmed: 27604037
Cancer Cell. 2016 Nov 14;30(5):683-693
pubmed: 27746144
J Exp Med. 2013 Aug 26;210(9):1711-28
pubmed: 23897983
PPAR Res. 2008;2008:930705
pubmed: 18509489
Cancer Sci. 2020 Jan;111(1):112-126
pubmed: 31675763
Cell Death Dis. 2019 May 28;10(6):416
pubmed: 31138790
Cancer Immunol Immunother. 2016 Nov;65(11):1303-1315
pubmed: 27520505
Hepatol Int. 2021 Feb;15(1):93-104
pubmed: 33420951
J Biol Chem. 2003 Nov 28;278(48):48275-82
pubmed: 14504269
Breast Cancer Res Treat. 2014 Jul;146(1):51-62
pubmed: 24878988
Clin Cancer Res. 2022 Jan 15;28(2):414-424
pubmed: 34728526
BMC Cancer. 2012 Dec 05;12:575
pubmed: 23216985
Cell Death Dis. 2022 Oct 31;13(10):916
pubmed: 36316327
Cell Rep. 2019 Jun 25;27(13):3927-3938.e6
pubmed: 31242424
Gastroenterology. 2019 Sep;157(3):744-759.e4
pubmed: 31154022
Anticancer Res. 2012 Jul;32(7):3007-13
pubmed: 22753765
Annu Rev Cell Dev Biol. 2006;22:129-57
pubmed: 16753029
Int J Biochem Cell Biol. 2020 Dec;129:105876
pubmed: 33166677
J Med Chem. 2012 Jun 14;55(11):4990-5002
pubmed: 22533316
Nat Commun. 2019 Jan 9;10(1):96
pubmed: 30626880
J Am Heart Assoc. 2020 Jan 21;9(2):e013754
pubmed: 31960736
BMC Cancer. 2015 Mar 27;15:189
pubmed: 25881076
Br J Pharmacol. 2021 Aug;178(16):3248-3260
pubmed: 32696532
Cancer Discov. 2011 Oct;1(5):442-56
pubmed: 22059152
Nat Methods. 2013 Mar;10(3):259-64
pubmed: 23396283
Cancer Lett. 2012 Nov 1;324(1):1-12
pubmed: 22542807
Blood. 2022 Jan 13;139(2):165-176
pubmed: 34610110
Breast Cancer Res Treat. 2013 Nov;142(2):389-98
pubmed: 24166281
J Clin Invest. 2021 Jan 4;131(1):
pubmed: 33393488
Mol Carcinog. 2018 Nov;57(11):1599-1607
pubmed: 30074275
Front Chem. 2020 Jun 18;8:516
pubmed: 32626692
Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2349-56
pubmed: 25304929
Circ Res. 2019 May 10;124(10):1505-1518
pubmed: 31071007
PLoS One. 2018 Feb 28;13(2):e0193318
pubmed: 29489864
Cell Death Dis. 2014 Jan 09;5:e990
pubmed: 24407243
Drug Resist Updat. 2020 Mar;49:100670
pubmed: 31846838
Mol Cell. 2019 Oct 17;76(2):220-231
pubmed: 31586545
Clin Biochem. 2007 Jun;40(9-10):575-84
pubmed: 17467679
Mol Med Rep. 2019 Oct;20(4):3003-3010
pubmed: 31432128